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ABSTRACT 
 
The ability to maintain skeletal muscle mass appears to be impaired in insulin resistant 
conditions that are characterised by muscle lipid accumulation, such as type 2 diabetes. The 
present study investigated the effect of acutely increasing lipid availability on muscle protein 
synthesis. Seven healthy young male volunteers underwent a 7 h intravenous infusion of L-
[ring-2H5]phenylalanine on two randomised occasions combined with either 0.9% saline or 
10% Intralipid at 100 mL/h. After a 4 h ‘basal’ period, a 21 g bolus of amino acids was 
administered and a 3 h euglycaemic hyperinsulinemic clamp was commenced (‘fed’ period). 
Muscle biopsies were obtained from the vastus lateralis at 1.5, 4, and 7 h. Lipid infusion 
reduced fed whole-body glucose disposal by 20%. Furthermore, whereas mixed muscle 
fractional synthetic rate increased from the basal to fed period during saline infusion by 2.2-
fold, no change occurred during lipid infusion, despite similar circulating insulin and leucine 
concentrations. This ‘anabolic resistance’ to insulin and amino acids with lipid infusion was 
associated with a complete suppression of muscle 4E-BP1 phosphorylation. We propose that 
increased muscle lipid availability may contribute to anabolic resistance in insulin resistant 
conditions by impairing translation initiation. 
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It has been proposed that the inability of skeletal muscle to adequately synthesise new protein 
in response to anabolic stimuli such as amino acids (termed ‘anabolic resistance’) is a key 
contributory factor to the muscle mass loss observed in a variety of conditions such as ageing, 
type 2 diabetes, disuse, and critical illness (e.g. 1, 2). A common feature of all these 
conditions is the inability of skeletal muscle glucose metabolism to respond adequately to 
insulin signalling (insulin resistance), which is thought to be a consequence of the 
intracellular accumulation of lipid within skeletal muscle (3). As insulin signalling is also 
integral to skeletal muscle amino acid delivery and metabolism, in particular playing a 
permissive role in regulating muscle protein synthesis via activation of the mammalian target 
of rapamycin complex 1 (mTOR) pathway (4, 5), it is possible that lipid-induced insulin 
resistance may contribute towards skeletal muscle anabolic resistance. Indeed, skeletal muscle 
protein synthesis in response to insulin and amino acids appears to be negatively related to 
whole body fat mass and insulin sensitivity in humans (6). Thus, it is important to elucidate 
the impact of excess lipid per se on insulin and amino acid stimulated skeletal muscle protein 
synthesis and the associated signalling pathways in vivo in humans, particularly if strategies 
to treat anabolic resistance are to focus on reducing skeletal muscle lipid accumulation and 
insulin resistance. 
 
The intravenous infusion of a lipid emulsion with heparin is routinely used to elevate free 
fatty acid availability and allows researchers to investigate the acute effects of lipid-induced 
insulin resistance on insulin signalling (7) and subsequent impairments in glucose uptake, 
storage and oxidation (8, 9). The present study investigated the impact of acutely elevating 
fatty acid availability to a concentration known to induce insulin resistance of glucose 
metabolism on the muscle protein synthetic response and associated signalling to amino acid 
ingestion in the presence of a controlled, steady-state circulating insulin concentration in 
humans.  
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RESEARCH DESIGN & METHODS 
 
Subjects 
Seven healthy male participants (age 23.0 ± 0.8 years, body mass 78.5 ± 3.8 kg, BMI 24.5 ± 
0.9 kg/m2) gave their written informed consent to participate in the present study, which was 
approved by the University of Nottingham Medical School Ethics Committee in accordance 
with the Declaration of Helsinki.  
 
Protocol 
Participants reported to the laboratory at 0800 on two randomized occasions, at least two 
weeks apart, following an overnight fast and having abstained from strenuous exercise for the 
previous 48 hours. On each visit the participants rested semi-supine on a bed whilst a 7 h 
intravenous infusion of L-[ring-2H5]phenylalanine (0.5 mg·kg
-1·h-1; Cambridge Isotopes 
Limited, MA, USA) was performed in combination with the infusion of 0.9% saline 
(‘Control’) or 10% Intralipid (‘Lipid’; Fresenuis Kabi, Germany) at a rate of 100 ml/h. During 
the lipid infusion heparin was infused at rate of 600 U/h to elevate plasma non-esterified fatty 
acid (NEFA) availability. After 4 h a 21 g bolus of amino acids (except phenylalanine and 
tyrosine; Tyrosidon, SHS International Ltd., UK) was administered in a 440 mL solution via a 
nasogastric tube to avoid issues with palatability. At the same time a 3-hour hyperinsulinemic 
(Actrapid, Novo Nordisk, Denmark) euglycaemic (20% dextrose, Baxter Healthcare, UK) 
clamp (10) was commenced at a rate of 50 mU·m-2·min-1. At t = 7 h, the Intralipid/saline, L-
[ring-2H5]phenylalanine, and insulin infusions were stopped, whereas the glucose infusion 
was continued until blood glucose concentration was stable.  
 
Sample collection and analysis 
Arterialized-venous blood was obtained from a heated hand vein (11) at t = 0, 1.5 h and every 
30 min thereafter. Plasma treated with tetrahydrolipostatin (30 µg/ml plasma) was analysed 
for NEFA (NEFA C kit, WAKO Chemicals, Germany) on an automated analyzer (ABX 
Page 4 of 19Diabetes
 5
Pentra 400, Horiba Medical Ltd., France). Plasma separated from EGTA treated blood was 
analysed for insulin concentration by ELISA (DRG diagnostics, Germany) and, after 
deproteinisation on ice with dry 5-sulfosalicylic acid, phenylalanine and leucine 
concentration, and L-[ring-2H5]phenylalanine enrichment by GC-MS (Agilent 7890A 
GC/5975C; MSD, Little Falls, USA) as previously described (12, 13).  
 
Muscle samples were obtained from the vastus lateralis at t = 1, 4.5, and 7 h using the 
Bergström needle biopsy technique, and immediately frozen in liquid nitrogen. Freeze-dried 
muscle separated free of visible blood, fat, and connective tissue was analysed for 
intracellular tissue free and protein-bound L-[ring-2H5]phenylalanine enrichments (12, 13), as 
well as acetylcarnitine and long-chain acyl-CoA (t = 1 and 7 h only) as previously described 
(9). The remaining ‘wet’ muscle was used to measure the total muscle protein content (t = 4.5 
and 7 h only) of phosphorylated Akt (serine473), mTOR (serine2448), and 4E-BP1 
(threonine
37/46
) by Western blot analysis using commercial antibodies (Cell Signalling, MA, 
USA) normalised to α-actin (Sigma-Aldrich Company Ltd., UK) to control for loading, as 
well as pyruvate dehydrogenase complex activation status (PDCa), both as described 
previously (9). 
 
Calculations 
Fractional rate of mixed muscle protein synthesis (FSR) was calculated by dividing the 
increment in enrichment in the product (i.e. protein-bound L-[ring-2H5]phenylalanine) by the 
enrichment of the precursor (i.e. plasma free L-[ring-2H5]phenylalanine; 13). To adjust for 
non-steady state plasma tracer enrichments during the fed period, precursor enrichments were 
calculated as the integral of the plasma L-[ring-2H5]phenylalanine enrichment (14, 15) 
 
Statistics 
A two-way ANOVA (time and treatment factors; GraphPad Prism 6, GraphPad Software Inc, 
USA) was performed to detect differences within and between groups for all measures 
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described. When a significant effect was observed, a Student’s t-test with Bonferroni 
correction was performed to locate differences. Statistical significance was declared at 
P<0.05. All the values
 
presented in text, Tables and Figures represent mean ± the standard 
error of the mean. 
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RESULTS 
 
Insulin resistance of glucose metabolism 
Steady-state plasma NEFA concentrations were elevated throughout the basal period in Lipid 
compared to Control (P<0.001; Figure 1A). Furthermore, plasma NEFA concentrations were 
supressed (P<0.001) by insulin and amino acid administration to a similar degree (-0.38 ± 
0.01 vs. -0.39 ± 0.01 mmol/l; Figure 1A) such that they remained greater in Lipid throughout 
the fed period (P<0.001; Figure 1A). This similar suppression of plasma NEFA concentration 
between Lipid and Control was reflected by similar-steady state blood glucose (4.51 ± 0.05 
vs. 4.52 ± 0.05 mmol/l, respectively) and plasma insulin concentrations (104 ± 5 vs. 99 ± 3 
mU/l, respectively; Figure 1B). However, there was a 20 ± 6% lower average glucose 
disposal during the final hour of the fed period in Lipid compared to Control (P<0.01; Figure 
1C) and a 56 ± 12% lower PDCa by the end of the fed period at 7 h (P<0.05; Figure 1D).  
 
Amino acid and lipid metabolism  
Plasma leucine and phenylalanine concentrations (Figure 2A and 2B, respectively) were both 
maintained at fasting concentrations throughout the basal period in Lipid and Control. 
Similarly, plasma L-[ring-2H5]phenylalanine enrichments remained at the same steady-state 
levels in Lipid and Control (Figure 2C). Insulin and amino acid administration resulted in a 
similar peak in plasma leucine concentration in Lipid and Control after 30 min of the fed 
period (P<0.001; Figure 2A). However, insulin and amino acid administration caused a steady 
decline in plasma phenylalanine concentration during Control such that it was 49 ± 3% lower 
during the final hour of the fed period compared to basal (P<0.001; Figure 2B). Furthermore, 
the degree of reduction in plasma phenylalanine concentration in response to insulin and 
amino acid administration was greater in Lipid (65 ± 3%; P<0.001) when compared with 
Control, such that steady-state phenylalanine concentrations were lower (P<0.001; Figure 
2B). However, this did not result in a greater L-[ring-2H5]phenylalanine enrichment during the 
final hour of the fed period in Lipid compared to Control (Figure 2C).   
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Basal mixed muscle FSR was the same in Lipid compared to Control (Figure 3A). However, 
whereas mixed muscle FSR increased from the basal to fed period in Control (P<0.05; Figure 
3A), it did not respond to insulin and amino acid administration in Lipid, such that it was 
significantly lower than Control (P<0.05; Figure 3A). This was despite similar intracellular 
muscle enrichment before and after insulin and amino acid administration (4.4 ± 0.3 to 6.0 ± 
0.3 MPE vs. 4.6 ± 0.3 to 5.9 ± 0.6 MPE for Lipid and Control, respectively). Furthermore, 
this lower rate of protein synthesis in Lipid coincided with an inhibition of the insulin- and 
amino acid-mediated decline in skeletal muscle long-chain acyl-CoA (P<0.05; Figure 3B) and 
acetylcarnitine (P<0.01; Figure 3C) content at t = 7 h in Control. 
 
Associated muscle signalling pathways 
The phosphorylation status of Akt, mTOR, and 4E-BP1 were the same after the basal period 
at t = 4 h in Lipid compared to Control. Insulin and amino acid administration increased the 
phosphorylation of Akt (P<0.05; Figure 4A), mTOR (P<0.01; Figure 4B), and 4E-BP1 
(P<0.001; Figure 4C) by 1.9-, 1.7-, and 2.9-fold, respectively, compared to basal in Control. 
However, whereas insulin and amino acid administration also increased mTOR 
phosphorylation by 1.5-fold from basal in Lipid (P<0.05; Figure 4B), the 1.8-fold increase in 
Akt phosphorylation was not significantly different (P=0.09; Figure 4A). Furthermore, Lipid 
infusion had no effect on 4E-BP1 phosphorylation at all such that it was less than half that of 
Control at the end of the fed period (P<0.01; Figure 4C).  
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DISCUSSION 
The concept that lipid-induced insulin resistance coincides with anabolic resistance is not 
new. Diet-induced obesity in mice (16) and rats (17) was shown to impair the activation of 
skeletal muscle protein synthesis in response to feeding, particularly in glycolytic muscle 
where there was chronic lipid infiltration (17). The whole body protein anabolic response to 
combined hyperinsulinaemia and hyperaminoacidaemia is also blunted in obese women when 
compared to lean individuals (18), and skeletal muscle protein synthesis in response to insulin 
and amino acids appears to be negatively related to whole body fat mass in humans (6). 
However, the contribution of excess lipid and insulin resistance to anabolic resistance cannot 
be determined from the associations described above as other confounding factors, 
particularly physical activity status, will also contribute to anabolic resistance (2, 19). Thus, 
the present study clearly demonstrates that excess lipid availability per se within skeletal 
muscle can induce both insulin resistance of skeletal muscle glucose metabolism and anabolic 
resistance of amino acid metabolism, independently of physical activity levels and diet-
induced changes in body composition. This was evidenced by reduced insulin-stimulated 
peripheral glucose disposal and skeletal muscle PDC activation by around 20 and 50%, 
respectively, and a complete prevention of a 2.2-fold increase in the rate of mixed muscle 
protein synthesis in response to the ingestion of 21 g of amino acids containing 2.3 g leucine. 
Furthermore, this inability of skeletal muscle to increase protein synthesis in response to 
insulin and amino acid administration appeared to be mediated in part via the repression of 
translation initiation at the level of 4E-BP1, which is in agreement with previous studies 
demonstrating that elevating lipid availability in rats and cells decreases muscle protein 
synthesis (20, 21).  
 
This is, to our knowledge, the first study to acutely induce anabolic resistance in humans via 
lipid administration. However, these findings are in contrast to the study of Katsanos et al 
(22), where lipid was intravenously administered at nearly twice the rate and there was no 
blunting of the 50% increase in muscle protein synthesis observed in response to the ingestion 
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of 7 g of essential amino acids. The differences are difficult to reconcile, but may be due to 
the hyperinsulinaemic euglycaemic clamp in the present study, which likely impaired fat 
oxidation and caused an accumulation of intracellular lipid metabolites (23). Indeed, this was 
reflected by greater muscle long-chain acyl-CoA and acetylcarnitine content during lipid 
infusion under insulin and amino acid stimulated conditions, which are sensitive markers of 
incomplete lipid oxidation and lipid accumulation (9, 24). Whilst a mechanistic link has not 
been established, these results offer compelling evidence that a common lipid-mediated 
intracellular signalling defect downstream of the Akt-mTOR signalling pathway may cause 
both lipid-induced insulin and anabolic resistance, and provide insight into how conditions of 
lipid-induced insulin resistance such as ageing, type 2 diabetes, disuse, and critical illness 
may be linked to accelerated muscle mass loss.  
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FIGURE LEGENDS 
 
Figure 1. Plasma NEFA concentration (A), plasma insulin concentration (B), whole-body 
glucose disposal (C), and PDCa (D) before (Basal 1.5-4 h) and after (Fed 4-7 h) the 
administration of 21 g of amino acids and a 3 h euglycaemic hyperinsulinaemic (∼100 mU/l) 
clamp during 7 h intravenous infusion of saline (Control; white circles) or 10% Intralipid 
(Lipid; black circles) at a rate of 100 ml/h. Values represent means ± SEM. ††† P<0.001, †† 
P<0.01, 
† 
P<0.05, Lipid significantly different from corresponding Control value. 
*** 
P<0.001, 
Control and Lipid during Fed significantly different from corresponding Basal steady-state. 
 
Figure 2. Plasma leucine concentration (A), plasma phenylalanine concentration (B), and 
plasma phenylalanine enrichment (C), before (Basal 1.5-4 h) and after (Fed 4-7 h) the 
administration of 21 g of amino acids and a 3 h euglycaemic hyperinsulinaemic (∼100 mU/l) 
clamp during 7 h intravenous infusion of saline (Control; white circles) or 10% Intralipid 
(Lipid; black circles) at a rate of 100 ml/h. Values represent means ± SEM. ††† P<0.001, Lipid 
significantly lower corresponding Control value. 
*** 
P<0.001, 
** 
P<0.01, Control and Lipid 
during Fed significantly different from corresponding Basal values. 
 
Figure 3. Skeletal muscle mixed protein fraction synthetic rate (A), long-chain acyl-CoA 
content (B) and acetylcarnitine content (C) before (Basal) and after (Fed) the administration 
of 21 g of amino acids and a 3 h euglycaemic hyperinsulinaemic (∼100 mU/l) clamp during 7 
h intravenous infusion of saline (Control; white bars) or 10% Intralipid (Lipid; black bars) at a 
rate of 100 ml/h. Values represent means ± SEM. † P<0.05, †† P<0.01, Lipid significantly 
lower than corresponding Control value.
 * 
P<0.05, 
*** 
P<0.001, Fed significantly greater from 
corresponding Basal values. 
 
Figure 4. Representative blots (top panel) and phosphorylation status of skeletal muscle Akt 
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serine473 (A), mTOR serine2448 (B), and 4E-BP1 threonine37/46 (C) before (Basal) and after 
(Fed) the administration of 21 g of amino acids and a 3 h euglycaemic hyperinsulinaemic 
(∼100 mU/l) clamp during 7 h intravenous infusion of saline (Control; white bars) or 10% 
Intralipid (Lipid; black bars) at a rate of 100 ml/h. Values represent means ± SEM. †† P<0.01, 
Lipid significantly lower than corresponding Control value.
 *** 
P<0.001, 
** 
P<0.01,
 * 
P<0.05, 
Fed significantly greater from corresponding Basal values. 
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